RESTORE is an initiative that aims to accelerate the availability of Advanced Therapies to patients and make Europe the spearhead of #advancedtherapies R&D.
A short movie about #advancedtherapies, the differences to conventional drug development, what can be, and has been already achieved with them and @RESTOREhorizon as an important player in this exciting health care revolution. Enjoy! @fet_eu
https://t.co/wLLkGmQtOr
Short documentary video from the New England Journal of Medicine on Sickle Cell Disease and Gene Therapy from Patient and Physician Perspectives https://t.co/jYaErLAUyf
7 #CGT's have been approved in the US and EU in 2022, for the first time ever or in new geographies/indications. Up to 3 more are on the way this year.
And how does the pipeline look for 2023 and beyond? Read our H1 2022 report to find out! 🧬📰 ➡️https://t.co/hTwyYRTkRC
📚 Dr. @Guido_Moll and colleagues summarize our more than 20 years of scientific experience in the clinical use of mesenchymal stem cells and placenta-derived decidua stromal cells in different clinical settings, from #GVHD to #ARDS.
https://t.co/PO91F4gonR
With @RESTOREhorizon and @FabioViola a gamestory based on CAR-T cells in ALL "Fragments of Life" is free available in Google Play and in Apple Play. Download and disseminate.
The Incredible Story of Emily Whitehead & CAR T-Cell Therapy : Oncology Times https://t.co/e0JpxjKciD
Named by the #WHO! 💫💫
The academic CART19 #ARI0001 cells receives its brand new INN (international nonpropietary name)!
⏩ Varnimcabtagene autoleucel ⏪
How should this be nicknamed??
var-cel? varni-cel?? other??
@hospitalclinic@idibaps@EHA_Hematology@TheEBMT@sehh_es
New gene therapy treatment resulted in sustained, clinically relevant benefits in children with Metachromatic Leucodystrophy: long term results published. https://t.co/FpjGR1OKvT
So what's new in the fight against unapproved stem cell therapies?
Well, that:
Under bill, patients in Nebraska would be informed that stem cell therapies aren't approved https://t.co/v4jQ9zTOPE via @owhnews
Barring the gates to the battleground: DDR1 promotes immune exclusion in solid tumors | Signal Transduction and Targeted Therapy https://t.co/veyEKcihS5